2000PubMedRequires access

[Angiotensin-converting enzyme inhibitors in the treatment of arterial hypertension].

Babadzhan Vd

Open publisher page 0 citations

Abstract

Angiotensin-converting enzyme (ACE) inhibitors have come into widespread use as a treatment option for patients with arterial hypertension, which fact can be explained by their apparent hypotensive effect, a small percent of side effects, protective effects on target organs, and a possibility of reversibility of essential hypertension- and symptomatic hypertensions-related changes in the cardiovascular system. There are a great many of drug preparations belonging in the group of ACE-inhibitors (capoten, enalapril, renitec (enalapril maleate), benazepril, quinapril, cilazopril, lizinopril, ramipril--to name but few of them. Specificities of different representatives of ACE-inhibitors, as to their clinical efficacy were found to be related to different pharmacokinetic properties of drugs.

About this research paper

What this paper is about

Angiotensin-converting enzyme (ACE) inhibitors have come into widespread use as a treatment option for patients with arterial hypertension, which fact can be explained by their apparent hypotensive effect, a small percent of side effects, protective effects on target organs, and a possibility of reversibility of essential hypertension- and symptomatic hypertensions-related changes in the cardiovascular system. There are a great many of drug preparations belonging in the group of ACE-inhibitors (capoten, enalapril, renitec (enalapril maleate), benazepril, quinapril, cilazopril, lizinopril, ramipril--to name but few of them. Specificities of different representatives of ACE-inhibitors, as to their clinical efficacy were found to be related to different pharmacokinetic properties of drugs.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Angiotensin-converting enzyme (ACE) inhibitors have come into widespread use as a treatment option for patients with arterial hypertension, which fact can be explained by their apparent hypotensive effect, a small percent of side effects, protective effects on target organs, and a possibility of reversibility of essential hypertension- and symptomatic hypertensions-related changes in the cardiovascular system. There are a great many of drug preparations belonging in the group of ACE-inhibitors (capoten, enalapril, renitec (enalapril maleate), benazepril, quinapril, cilazopril, lizinopril, ramipril--to name but few of them. Specificities of different representatives of ACE-inhibitors, as to their clinical efficacy were found to be related to different pharmacokinetic properties of drugs.

Key concepts: Quinapril, Ramipril, Enalapril, Medicine, Benazepril, Angiotensin-converting enzyme, Pharmacology, Essential hypertension

Related papers

Back to paper searchBrowse research topicsOriginal source
[Angiotensin-converting enzyme inhibitors in the treatment of arterial hypertension]. — Research Paper | ScholarLens